Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Horizant

- PMLiVE

Survey reveals ongoing chemotherapy shortages in US cancer centres

Carboplatin shortages increased by 2% since the first NCCN survey in June 2023

- PMLiVE

GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

US survey reveals ‘critical’ drug shortages are affecting cancer care

Approximately 99% of US pharmacists reported that they are experiencing drug shortages

- PMLiVE

GSK discovers strain of bacterium that stops malaria transmission

It is hoped that the discovery could contribute to the eradication of the disease

- PMLiVE

GSK files lawsuit against Pfizer over RSV vaccine patent infringement

The RSV vaccine market is estimated to exceed $5bn and could surpass $10bn by 2030

- PMLiVE

GSK’s Jemperli combination receives FDA approval for endometrial cancer

Approximately 60,000 new cases of endometrial cancer are diagnosed every year in the US

- PMLiVE

GSK’s RSV vaccine Arexvy granted approval by MHRA for older adults

RSV infections in older adults account for about 14,000 hospitalisations each year in the UK

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

There are no approved vaccines offering simultaneous protection against all five serogroups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links